Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023
DeCuir J, Surie D, Zhu Y, Lauring A, Gaglani M, McNeal T, Ghamande S, Peltan I, Brown S, Ginde A, Steinwand A, Mohr N, Gibbs K, Hager D, Ali H, Frosch A, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Mosier J, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Rhoads J, Swan S, Johnson C, Lewis N, Ellington S, Dawood F, McMorrow M, Self W, Network F. Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023. Influenza And Other Respiratory Viruses 2024, 18: e70027. PMID: 39496339, PMCID: PMC11534416, DOI: 10.1111/irv.70027.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationIn-hospital outcomesVaccine effectivenessMonovalent dosesAbsolute VETest-negative case-control designInvasive mechanical ventilationCOVID-19 vaccineMultivariate logistic regressionSevere COVID-19Case patientsCase-control designControl patientsMechanical ventilationUnvaccinated patientsPatientsMonovalent vaccineCOVID-19-like illnessDoseCOVID-19 vaccine effectivenessBivalent vaccineLogistic regressionAdmission dateVaccineHospitalInterim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024
DeCuir J, Payne A, Self W, Rowley E, Dascomb K, DeSilva M, Irving S, Grannis S, Ong T, Klein N, Weber Z, Reese S, Ball S, Barron M, Naleway A, Dixon B, Essien I, Bride D, Natarajan K, Fireman B, Shah A, Okwuazi E, Wiegand R, Zhu Y, Lauring A, Martin E, Gaglani M, Peltan I, Brown S, Ginde A, Mohr N, Gibbs K, Hager D, Prekker M, Mohamed A, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Chang S, Mallow C, Kwon J, Exline M, Columbus C, Vaughn I, Safdar B, Mosier J, Harris E, Casey J, Chappell J, Grijalva C, Swan S, Johnson C, Lewis N, Ellington S, Adams K, Tenforde M, Paden C, Dawood F, Fleming-Dutra K, Surie D, Link-Gelles R, Collaborators C, Collaborators C, Ghamande S, Gottlieb R, McNeal T, Raver C, Bender W, Fletcher L, Heaton P, Kane S, McEvoy C, Thapa S, Vazquez-Benitez G, Frosch A, Lamerato L, Ramesh M, Arnofer J, Ali H, Hopkins J, Crane B, Dandamudi P, Goddard K, Hansen J, Timbol J, Zerbo O, Allen K, Duszynski T, Fadel W, Rogerson C, Qadir N, Chavez C, Doyle B, Mayer D, Rao S, Rivas C, Johnson N, Baughman A, Lwin C, Rhoads J, Womack K, Dunne M, Ciesla A, Mak J, Najdowski M, Ray C. Interim Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024. MMWR Morbidity And Mortality Weekly Report 2024, 73: 180-188. PMID: 38421945, PMCID: PMC10907041, DOI: 10.15585/mmwr.mm7308a5.Peer-Reviewed Original ResearchConceptsVaccine effectivenessEmergency departmentCOVID-19 vaccineCDC's Advisory CommitteeCOVID-19-associated hospitalizationUrgent careCOVID-19 vaccine dosesImmunocompetent adultsMedian intervalCase-control designVE estimatesVaccine doseImmunization PracticesTest-negativeSevere diseaseCDC recommendationsDoseVaccineHospitalVE networkCOVID-19CDCMonthsAdvisory CommitteeDays